Effect of Repeated Administration of Liraglutide on Insulinogenic Indices
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02089256|
Recruitment Status : Completed
First Posted : March 17, 2014
Last Update Posted : April 1, 2015
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: Liraglutide||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Repeated Administration of Liraglutide on Insulinogenic Indices|
|Study Start Date :||June 2014|
|Actual Primary Completion Date :||March 2015|
|Actual Study Completion Date :||March 2015|
Liraglutide 0.6 mg/day subcutaneously.
Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.
GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection).
Other Name: Victoza
- Change in the glucose-sensitivity of the beta cells [ Time Frame: baseline, first dose, after 3-weeks on treatment ]Graded glucose infusion test will be used to create insulin secretion rate- plasma glucose curve. The primary outcome is the change of the slope of the curve from baseline after acute administration of liraglutide compared to the repeated administration (after 3-weeks of treatment).
- Effects on adrenal hormones [ Time Frame: baseline, acute administration, 3 weeks ]change in ACTH/cortisol levels and renin / aldosterone levels after acute and repeated administration of liraglutide.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02089256
|Tartu University Hospital|
|Principal Investigator:||Vallo Volke, MD||Tartu University|